RT @BoeckmannMalte: @Karl_Lauterbach @C_Scheibenbogen Vielen Dank Herr Lauterbach! Bitte denke sie über die Zulassung des Medikaments Ampli…
@Karl_Lauterbach @C_Scheibenbogen Vielen Dank Herr Lauterbach! Bitte denke sie über die Zulassung des Medikaments Ampligen (Rintatolimod) in DE nach. Es gibt mehrere Studien die eine Wirksamkeit suggerieren. Außerdem ist Ampligen bereits in Argentinien für
https://t.co/oFgAY71JXy "Rintatolimod produced objective improvement in ET (exercise tolerance) and a reduction in CFS/ME related concomitant medication usage as well as other secondary outcomes." #MECFS #Ampligen
A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome #MECFS #Ampligen https://t.co/oFgAY71JXy
@JKBurmeister @eschersillusion @oslersweb I thought the results of the phase III trial were disappointing: A just barely statistically significant increase in walking time, no improvement in vitality or general health perception. https://t.co/mttyuTDQh9
Interesting how long covid got two million, obvious how NIH finds it too complex. Interesting how LC has trials for Ampligen 65 million prior with myalgic encephalomyelitis are dying! Decades bedridden? https://t.co/ShSSF9P3hT
@Saltykid41 Here's one study. I'm not well-versed in this area & need to research more. https://t.co/CC7ccawbYX
@postviraltrials @coco_chatel They had a pretty poor primary outcome measure: treadmill performance https://t.co/jJA1X8FrMP
In the paper the investigators only reported: “Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF 36).” https://t.co/Xfc7i8VVrj
RT @neurostingl: Eine größere Studie 2012 zeigte eine Verbesserung der Aktivitätstoleranz um mindestens 25% bei 39% v 23% in der Placebogru…
RT @neurostingl: Eine größere Studie 2012 zeigte eine Verbesserung der Aktivitätstoleranz um mindestens 25% bei 39% v 23% in der Placebogru…
RT @neurostingl: Eine größere Studie 2012 zeigte eine Verbesserung der Aktivitätstoleranz um mindestens 25% bei 39% v 23% in der Placebogru…
Eine größere Studie 2012 zeigte eine Verbesserung der Aktivitätstoleranz um mindestens 25% bei 39% v 23% in der Placebogruppe. Der Effekt ist offenbar dann größer, wenn der Krankheitsbeginn weniger als 8 Jahre zurück liegt: https://t.co/ICb1sLrIMA 3/n
@positivepolly06 https://t.co/gdgWV3Rb0Y By week 40, the rintatolimod cohort (n = 100) had a mean change increase in exercise tolerance of 96 SECONDS to 672. The placebo group (n = 108) increased ET by 28 seconds to 616 sec. https://t.co/LuIFFp4L0n
RT @CyruxiME: @oslersweb @twoShaws You often tweet about Ampligen so I looked at the results of their phase 3 trial (https://t.co/Xfc7i8Ekz…
@PlzSolveCFS @AimImmuno Even if that's a typo (for 12 - 48) on transcription to online format, their own studies from 2012 and 2020 publications were far from impressive: https://t.co/1g4UuElZdw https://t.co/B2FbpRMXvY I'm not stopping anyone from signing
@oslersweb @twoShaws You often tweet about Ampligen so I looked at the results of their phase 3 trial (https://t.co/Xfc7i8EkzL). Not impressed. A mean change of 11.4% in exercise duration and essentially no improvement on secondary outcomes like quality of
@loscharlos @DreamingTheMind @winstoncb Most likely yes, but of course I don't know the specifics of the case. There was a double blind placebo controlled clinical trial of Ampligen for ME/CFS which showed that on average there are some very small benefits
@Petra_ikhebME_ Ampligen is the only drug I have seen so far that improves exercise tolerance - getting at a core feature of the disease (impaired energy metabolism). https://t.co/YOmVkQ3kVr
@MackayIM Rather than anti-viral's for Post-Ebola PEVDS check out these TLR-3 Agonists http://t.co/8hJpwjyouJ and http://t.co/NvALuJnRO4
@nick_clegg RT @UKFreeNews Dear #gov #NHS stop being cruel & give us the Ampligen now please http://t.co/P2HIQ6nz and http://t.co/NlucuWLT
PLoS ONE: A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintat...Thanks to... http://t.co/hRxpBj7f
$HEB Ampligen Phase III peer review article : http://t.co/gzvri9Mc
Rintatolimod improved exercise tolerance in chronic fatigue syndrome/myalgic encephalomyelitis patients: http://t.co/CFldYBXd #CFS #ME
RT @sproggled: Ampligen VS Placebo double blinded clinical trial for severely affected pts with #NeuroME http://t.co/cIwx9udG
12-center trial of #Ampligen treatment for severe #mecfs reports positive results #rheum @nihforhealth http://t.co/TtlHHFGf
RT @sproggled: Ampligen VS Placebo double blinded clinical trial for severely affected pts with #NeuroME http://t.co/cIwx9udG
RT @TomKindlon: Free full text: RCT of TLR-3 Agonist Rintatolimod [Ampligen] in Severe #CFS http://t.co/LFlASFIO #MECFS #NeuroME #Spoonie
A double-blind placebo-controlled study of Ampligen (rintatolimid) showed improvement in exercise testing... http://t.co/E9RWUxXN
@MEAssociation Do you think this trial http://t.co/2PUmgM5G might mean it becomes available for prescription..? I want some :P lol
Finally a clinical trial that has enrolled severely debilitated cases of ME/CFS. A small but - sponsored by pharma http://t.co/OZBORWeB
Big RCT-study on an immune modulating drug in 234 ME/CFS patients published in PLoS ONE today. Positive findings http://t.co/OZBORWeB
Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of CFS http://t.co/AjOB1vRv
RT @EsME_ICC: PLoS ONE: A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of Ampligen http://t.co/MVhateYg”
PLoS ONE: A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of Ampligen http://t.co/MVhateYg”
PLoS ONE: A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintat http://t.co/coeeV5A1
The latest Facebook post by ME/CFS-Evolving Science http://t.co/AyROwHtM
Uusi tutkimus Ampligenista CFS/ME:ssä, tällä kertaa vaikeassa. http://t.co/wv96cqwT Josko FDA kohta hyväksyisi lääkkeen?
RT @TomKindlon: Free full text: RCT of TLR-3 Agonist Rintatolimod [Ampligen] in Severe #CFS http://t.co/LFlASFIO #MECFS #NeuroME #Spoonie
Ampligen VS Placebo double blinded clinical trial for severely affected pts with #MECFS @healthcanada @leonaaglukkaq http://t.co/6uSKfeV3
RT @TomKindlon: Free full text: RCT of TLR-3 Agonist Rintatolimod [Ampligen] in Severe #CFS http://t.co/LFlASFIO #MECFS #NeuroME #Spoonie
RT @TomKindlon: Free full text: RCT of TLR-3 Agonist Rintatolimod [Ampligen] in Severe #CFS http://t.co/LFlASFIO #MECFS #NeuroME #Spoonie
Free full text: RCT of TLR-3 Agonist Rintatolimod [Ampligen] in Severe #CFS http://t.co/LFlASFIO #MECFS #NeuroME #Spoonie